A phase II study of weekly docetaxel for patients with advanced or recurrent cancer of the cervix

Gynecologic and Obstetric Investigation

Volumn 64, Issue 4, 2007, Pages 193-198

  Pearl, Michael L ^a,d   Johnston, Carolyn M ^b   McMeekin, D Scott ^c  

^a STONY BROOK UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

Cervical cancer, advanced; Cervical cancer, recurrent; Docetaxel; Phase II study

Indexed keywords

DOCETAXEL;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; BONE MARROW; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; KIDNEY FUNCTION; LACRIMATION DISORDER; LIVER FUNCTION; METASTASIS; MULTIPLE CYCLE TREATMENT; PAIN; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OKLAHOMA; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 36048976253     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106489     Document Type: Article

References (24)

1. American Cancer Society. Cancer Facts and Figures, 1999.
2. Omura GA: Current status of chemotherapy for cancer of the cervix. Oncology 1992;6:27-32.
3. Thigpen JT, Shingleton H, Homesley H, Lagasse L, Blessing J: Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. Cancer 1981;48:899-903.
4. Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ: Randomized trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985;3:1079-1085.
5. Omura GA, Blessing JA, Vaccarello L, Berman ML, Clarke-Pearson DL, Mutch DG, Anderson B: Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1997;15:165-171.
6. Brand E, Berek JS, Hacker NF: Controversies in the management of cervical adenocarcinoma. Obstet Gynecol 1988;71:261-269.
7. Look KY, Brunetto VL, Clarke-Pearson DL, Averette HE, Major FJ, Alvarez RD, Homesley HD, Zaino RJ: An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1996;63:304-311.
8. Eifel PJ, Burke TW, Morris M, Smith TL: Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 1995;59:38-44.
9. Diagnosis and treatment of cervical carcinomas. ACOG Practice Bulletin # 35. Obstst Gynecol 2002;99:855-867.
10. Thigpen JT, Blessing JA, Fowler WC Jr, Hatch K: Phase II trials of cisplatin and piperazinedione as single agents in the treatment of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study Cancer Treat Rep 1986;70:1097-1100.
11. Slayton RE, Blessing JA, Homesley HD: Phase II trial of etoposide in the management of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Cancer Treat Rep 1984;68:1513-1514.
12. Curtin JP, Blessing JA, Webster KD, Rose PG, Mayer AR, Fowler WC Jr, Malfetano JH, Alvarez RD: Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2001;19:1275-1278.
13. Riou JF, Naudin A, Lavelle F: Effects of taxotere on murine and human tumor cell lines. Biochem Biophys Res Comm 1992;187:164-170.
14. Aapro M, Braakhuis B, Dietel M, Hill B, Kelland L, Levieveild P, Silvestrini R, Zoli W: Superior activity of taxotere (ter) over taxol (tol) in vitro. Proc Am Assoc Cancer Res 1992;33:3086.
15. Kelland LR, Abel G: Comparative in vitro toxicity of taxol and taxotere against cisplatin-sensitive and resistant human ovarian cancer cell lines. Cancer Chemother Pharmacol 1992;30:444-450.
16. Diaz JF, Andreu JM: Assembly of purified GDP-tubulin into microtubules indiuced by taxol and taxotere: reversibility, ligand stoichiometry and competition. Biochemistry 1993;32:2747-2755.
17. Francis P, Schneider J, Hann L, Balmaceda C, Barakat R, Phillips M, Hakes T: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994;12:2301-2308.
18. Piccart MJ, Gore M, ten Bokkel Huinink W, Van Oosterom A, Verweij J, Wanders J, Franklin H, Bayssas M, Kaye S: Docetaxel, a new drug for the treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995;87:676-681.
19. Kavanagh JJ, Kudelka AP, de Leon CG, Tresukosol D, Hord M, Finnegan MB, Kim EE, Varma D, Forman A, Cohen P, Edwards CL, Freedman RS, Verschraegen CF: A phase II trial of docetaxel in patients with epithelial ovarian cancer refractory to platinum. Clin Cancer Res 1996;2:837-842.
20. Stemmler J, Mair W, Stauch M, Deutsch G, Abenhardt W, Dorn B, Kentenich C, Malekmohammadi M, Jackish C, Leinung S, Brudler O, Venling-Kaiser U, Stamp J, Heinemann V: High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer. Oncol 2005;68:71-78.
21. Gridelli C, Gallo C, Di Maio M, Illiano A, Salvagni S, Piantedosi FV, Palazzolo G, Caffo O, Ceribelli A, Falcone A, Mazzanti P, Brancaccio L, Capuano MA, Isa L, Barbera S, Perrone F: A randomized clinical trial of two docetaxel regimens (weekly vs. 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Ca 2004;91:1996-2004.
22. Simon R: Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 1989;10:1-10.
23. Gallo D, Ferlini C, Distefan M, Cantelmo F, Gaggini C, Fattorossi A, Riva A, Bombardelli E, Proietti E, Manusco S, Scambia G: Antitumour activity of a panel of taxanes toward a cellular model of human cervical cancer. Cancer Chemother Pharmacol 2000;45:127-132.
24. Kudelka AP, Verschraegen CF, Levy T, Edwards CL, Fishman A, Freedman RS, Kaplan A, Kieback DG, Mante R, Ende K, Steger M, Kavanagh JJ: Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix. Anti-Cancer Drugs 1996;7:398-401.